Merck Global Health Innovation Fund invests in Octave Bioscience to continue expanding its transformative care management platform for neurodegenerative diseases.

“Octave’s approach to improve patient outcomes in multiple sclerosis is powerful and we believe will have broader neurodegenerative disease applications,” said David M. Rubin, Ph.D., Managing Director of Merck GHIF. “We look forward to working with the team as they continue to craft their platform focused on multi-modality, integrated findings and expanded disease insights.” (Business Wire)